undamentalytics Newsletter
Sign in

Gyre Therapeutics, Inc. cash flow statement

In fiscal 2025, Gyre Therapeutics, Inc.'s operations generated $1.0m of cash; it spent $1.2m on capital projects, leaving free cash flow of −$180,000.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142017Dec 20172018Dec 20182020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−24138−84−64−41−6−20−29−55−841126−41−5
Depreciation and amortisation222211000011223
Stock-based pay25980013431371710
Capital spending03100000—159211
Free cash flow−24135−85−65−41−6−20−29—−85617−6−0−6
Free cash flow after stock pay−27130−94−72−41−7−21−32—−88−810−7−7−16
Dividends paid——————————45————
Shares issued493831005————31——

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: GYRE vs NAGEETON vs GYREGYRE vs ZVRA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Gyre Therapeutics, Inc.